Rising demand for novel therapeutics among aging population will enable growth in the Global Glaucoma Therapeutics Market. Recently Fortune Business Insights has published a report, titled “Glaucoma Therapeutics: Global Market Analysis, Insights and Forecast, 2019-2026.” According to the report, in 2018 the global market was worth US$ 6273.5 Mn. However, the global market is anticipated to expand at a CAGR of 6.1% and reach US$ 10,091 Mn by the end of 2026. The report also classifies the market on the basis of various segments.
By Drug Class
- Beta Blockers
- Alpha Adrenergic Agonists
- Carbonic Anhydrase Inhibitors
- Combination Drugs
By Disease Indication
- Open Angle Glaucoma
- Angle Closure Glaucoma
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
According to the report glaucoma therapeutics market in North America was worth US$ 2405.9 Mn in 2018. The region is expected to dominate the global market during the forecast period 2019-2026. The growth predicted in North America is attribute to its constantly improving healthcare facilities and adoption of recent advances in glaucoma diagnosis, treatment, and medication. These factors also are expected to bode well for the global glaucoma therapeutics market. Meanwhile, the increasing number of glaucoma cases in nations such as China and India is projected to enable growth in Asia Pacific. Additionally, the region is anticipated to progress at a relatively high CAGR.
“Public authorities and governments are adoption several initiatives to create awareness about glaucoma and aid in the cure and prevention of glaucoma. This is projected to generate demand in the market,” said a lead analyst at Fortune Business Insights.
- include Pfizer, Inc.,
- Merck & Co., Inc.,
- Bausch & Lomb Incorporated,
- Teva Pharmaceutical Industry,
- Aerie Pharmaceuticals,
- Pfizer, Inc.,
- Inotek Pharmaceuticals.
Allergan and Novartis AG, Together Leading the Global Market Since 2018
The global glaucoma therapeutics market is witnessing an influx of new players. Allergan and Novartis AG, are currently leading players in the global market. The companies are involved in manufacturing and marketing of prostaglandin analogues. Among, prostaglandin analogues Lumigan and Travatan are the two most preferred medications for the treatment of glaucoma. Quality production and marketing of these drugs have enabled the organizations establish a stronghold in the global market. Besides this, other companies operating in the market are Pfizer, Inc., Merck & Co., Inc., Bausch & Lomb Incorporated, Teva Pharmaceutical Industry, Aerie Pharmaceuticals, Pfizer, Inc., and Inotek Pharmaceuticals.
In December 2017, Aerie Pharmaceuticals Inc. introduced new eye drops called Rhopressa. The eye drop is specially designed for faster treatment of glaucoma. This may also positively impact the organization’s current position in the market and enable it gain higher share in the global glaucoma therapeutics market.
More Trending Topics From Fortune Business [email protected]